💡 Did you know?
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
History
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
The BSE, founded in 1875, is Asia's oldest stock exchange — it started under a banyan tree on Dalal Street, where the bronze bull stands today.
Sanofi India Limited is an India-based company, which is engaged in the business of manufacturing and trading of drugs and pharmaceuticals. The Company produces pharmaceutical formulations, dosage forms and offer a range of medicines across various therapeutic areas. Its…
Weekly engine runs — movement reflects the numbers, not analyst opinion.
A decent, fast-growing business, trading cheap versus its own history.
Sanofi India is scored on the pharma / healthcare framework. It keeps a fat 20.4% of every rupee of sales as net profit. Those profits are backed by real cash — operating cash flow runs 1.12× reported profit. It throws off free cash worth 5.5% of its market value — a strong free-cash yield.
Over the last 3 years revenue compounded at 44%/yr and profit at 58%/yr. Net worth has actually shrunk (-15%/yr) — value is not being built. Return on equity is an elite 47.1%. In the latest quarter profit grew 11% versus the prior quarter.
At 18× earnings, the stock sits at the 13th percentile of its own 2.9-year range — the cheap end of where it has historically traded. Today's price implies ~16%/yr earnings growth for a decade. The books come through clean — a forensic grade of A, and Altman puts distress risk in the safe zone.
A plain-English restatement of the figures on this page — rules-based, for education and research context, not investment advice or a recommendation.
| Ratio | Company | Sector | Read |
|---|---|---|---|
| P/E | 34.06 | — | — |
| P/B | 16.36 | 4.11 | worse |
| EV/EBITDA | 24.25 | 19.15 | worse |
| ROE | 47.13 | — | — |
| ROCE | 47.95 | — | — |
| ROA | 46.03 | — | — |
| Quick Ratio | 0.87 | 4.8 | worse |
| Peer | P/E | P/B | ROE |
|---|---|---|---|
| Sun Pharmaceutical Industries | 40.6 | 5.0 | 13.8% |
| Divis Laboratories | 93.5 | 16.3 | 15.3% |
| Torrent Pharmaceuticals | 85.9 | 9.8 | 11.4% |
Negative CAGR — the top line has shrunk over this window.
Revenue is outpacing profit (-1% vs -31%) — costs are rising faster than the top line. The latest year saw a -31% swing — check if it's a one-off or structural.
Operating margin has compressed from 26% to 21% — costs or competition are eating into profitability. The gap between operating and net margin is widening — interest or tax costs are rising.
ROE at 36% — the business earns well above its cost of equity. ROE powered by fat margins — the hallmark of a high-quality franchise with pricing power.
EPS dropped in the latest year despite possible profit changes — dilution or a profit dip could be at play. -31% EPS CAGR — this is the rate at which each share's claim on earnings is compounding.
Operating cash flow has been positive every year — the business generates real cash, not just accounting profit. Financing outflows in consecutive years — balance-sheet discipline through debt repayment or dividends.
When operating cash keeps pace with reported profit, earnings are cash-backed; a persistent shortfall is a quality flag.
Revenue broadly flat QoQ — stable but not accelerating.
Profit jumped 11% QoQ — check if this is operating leverage or a one-off item. Quarterly margins are compressing (27% → 18%) — more revenue isn't translating to proportionally more profit.
How today's P/E compares to the stock's own historical range. Dashed line = the 2.9y median.
Promoter holding at 60.4% — majority control intact.
Produced by a rules-based engine over licensed exchange fundamentals — every sentence above is derived from the numbers shown, no analyst or AI opinion involved. Education and research context, not investment advice. We are not SEBI-registered as an Investment Adviser or Research Analyst.